Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 3.04 AUD -4.1% Market Closed
Market Cap: 247m AUD

Wall Street
Price Targets

MYX Price Targets Summary
Mayne Pharma Group Ltd

Wall Street analysts forecast MYX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYX is 6.22 AUD with a low forecast of 6.16 AUD and a high forecast of 6.41 AUD.

Lowest
Price Target
6.16 AUD
103% Upside
Average
Price Target
6.22 AUD
105% Upside
Highest
Price Target
6.41 AUD
111% Upside
Mayne Pharma Group Ltd Competitors:
Price Targets
4547
Kissei Pharmaceutical Co Ltd
8% Upside
GS71
GSK plc
0% Downside
AETHER
Aether Industries Ltd
24% Upside
ABBOTINDIA
Abbott India Ltd
32% Upside
INDOCO
Indoco Remedies Ltd
14% Upside
4565
Sosei Group Corp
116% Upside
200670
Humedix Co Ltd
68% Upside
TLRY
Tilray Brands Inc
23% Upside

Revenue
Forecast

Revenue Estimate
Mayne Pharma Group Ltd

For the last 7 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -4%. The projected CAGR for the next 2 years is 13%.

-4%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
19%
Average Beat

Net Income
Forecast

Net Income Estimate
Mayne Pharma Group Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MYX's stock price target?
Price Target
6.22 AUD

According to Wall Street analysts, the average 1-year price target for MYX is 6.22 AUD with a low forecast of 6.16 AUD and a high forecast of 6.41 AUD.

What is Mayne Pharma Group Ltd's Revenue forecast?
Projected CAGR
13%

For the last 7 years the compound annual growth rate for Mayne Pharma Group Ltd's revenue is -4%. The projected CAGR for the next 2 years is 13%.

Back to Top